following a full submission:
insulin glargine/lixisenatide (Suliqua®) is accepted for restricted use within NHSScotland.
Indication under review: In combination with metformin for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal insulin.
SMC restriction: for use in patients who are uncontrolled on basal insulin (glycosylated haemoglobin [HbA1c] > 7.5% [59mmol/mol]) and for whom a GLP-1 receptor agonist is appropriate as an add-on intensification therapy to basal insulin analogues.
Insulin glargine/lixisenatide improved glycaemic control compared with insulin glargine alone in adults with inadequately controlled type 2 diabetes mellitus.
Medicine details
- Medicine name:
- insulin glargine/lixisenatide (Suliqua)
- SMC ID:
- SMC2235
- Indication:
In combination with metformin for the treatment of adults with type II diabetes mellitus (T2DM), to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal insulin.
- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 April 2020